Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

ERG rearrangements (most commonly transmembrane protease, serine 2 [TMPRSS2]:ERG [T2:ERG] gene fusions) have been identified in approximately 50% of prostate cancers . Quantification of T2:ERG in postdigital rectal examination urine, in combination with PCA3, improves the performance of serum prostate-specific antigen for prostate cancer prediction on biopsy. Here we compared urine T2:ERG and PCA3 scores with ERG+ (determined with immunohistochemical analysis) and total prostate cancer burden in 41 mapped prostatectomies. Prostatectomies had a median of 3 tumor foci (range, 1-15) and 2.6 cm of summed linear tumor dimension (range, 0.6-7.1 cm). Urine T2:ERG score correlated most with summed linear ERG+ tumor dimension and number of ERG+ foci (r(s) = 0.68 and 0.67, respectively, both P < .001). Urine PCA3 score showed weaker correlation with both number of tumor foci (r(s) = 0.34, P = .03) and summed linear tumor dimension (r(s) = 0.26, P = .10). In summary, we demonstrate a strong correlation between urine T2:ERG score and total ERG+ prostate cancer burden at prostatectomy, consistent with high tumor specificity.

[1]  A. Chinnaiyan,et al.  Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. , 2012, Archives of pathology & laboratory medicine.

[2]  Y. Allory,et al.  The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy , 2012, BJU international.

[3]  G. Jenster,et al.  ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer , 2012, Modern Pathology.

[4]  Isabell A. Sesterhenn,et al.  Clinical potential of the ERG oncoprotein in prostate cancer , 2012, Nature Reviews Urology.

[5]  Mesut Remzi,et al.  The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance , 2012, BJU international.

[6]  G. Kristiansen,et al.  ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies , 2012, Prostate Cancer and Prostatic Diseases.

[7]  M. Cooperberg,et al.  Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer , 2011, Prostate Cancer and Prostatic Diseases.

[8]  R. Shah,et al.  Atypical Glands Suspicious for Cancer , 2012 .

[9]  Arul M Chinnaiyan,et al.  Common gene rearrangements in prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[11]  G. Andriole,et al.  Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. , 2011, Urology.

[12]  J. Trapman,et al.  Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice , 2011, Modern Pathology.

[13]  T. Tsuzuki,et al.  ERG gene rearrangement status in prostate cancer detected by immunohistochemistry , 2011, Virchows Archiv.

[14]  T. Daly,et al.  The Utility of ERG/P63 Double Immunohistochemical Staining in the Diagnosis of Limited Cancer in Prostate Needle Biopsies , 2011, The American journal of surgical pathology.

[15]  T. D. de Reijke,et al.  Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. , 2011, The Journal of urology.

[16]  M. Colombel,et al.  Urinary PCA3 score predicts prostate cancer multifocality. , 2011, The Journal of urology.

[17]  M. Rubin,et al.  The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With “Atypical Glands Suspicious for Cancer” , 2011, The American journal of surgical pathology.

[18]  L. Salomon,et al.  Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.

[19]  J. Groskopf,et al.  PCA3: from basic molecular science to the clinical lab. , 2011, Cancer letters.

[20]  A. Haese*,et al.  Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. , 2011, European urology.

[21]  G. Andriole,et al.  PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. , 2010, The Journal of urology.

[22]  R. V. D. van den Bergh,et al.  Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. , 2010, European urology.

[23]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[24]  S-H Tan,et al.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.

[25]  A. Taille,et al.  Urine biomarkers in prostate cancer , 2010, Nature Reviews Urology.

[26]  M. Rubin,et al.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.

[27]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[28]  M. Gerstein,et al.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. , 2009, Neoplasia.

[29]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[30]  R. Dhir.  PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance , 2009 .

[31]  S. Srivastava,et al.  PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. , 2008, The Journal of urology.

[32]  Mesut Remzi,et al.  Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.

[33]  M. Loda,et al.  Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.

[34]  P. Troncoso,et al.  PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.

[35]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[36]  S. Srivastava,et al.  Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.

[37]  R. Shah,et al.  Partial Atrophy in Prostate Needle Biopsies: A Detailed Analysis of Its Morphology, Immunophenotype, and Cellular Kinetics , 2008, The American journal of surgical pathology.

[38]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[39]  G. Beaudry,et al.  Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization , 2007, Modern Pathology.

[40]  M. Rubin,et al.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.

[41]  Adam S. Kibel,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007 .

[42]  R. Shah,et al.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.

[43]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[44]  L. Marks,et al.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.

[45]  J. Epstein,et al.  Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. , 2006, The Journal of urology.

[46]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[47]  John T. Wei,et al.  Use of extended pattern technique for initial prostate biopsy. , 2005, The Journal of urology.

[48]  Ximing J. Yang,et al.  Analysis of α-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia , 2004 .

[49]  Lang Li,et al.  Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.

[50]  Ximing J. Yang,et al.  Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. , 2004, Human pathology.

[51]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[52]  J Alfred Witjes,et al.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. , 2003, European urology.

[53]  A. Gown,et al.  P504S Immunohistochemical Detection in 405 Prostatic Specimens Including 376 18-Gauge Needle Biopsies , 2002, The American journal of surgical pathology.

[54]  Ximing J. Yang,et al.  P504S/&agr;-Methylacyl-CoA Racemase: A Useful Marker for Diagnosis of Small Foci of Prostatic Carcinoma on Needle Biopsy , 2002, The American journal of surgical pathology.

[55]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[56]  Ximing J. Yang,et al.  Expression of &agr;-Methylacyl-CoA Racemase (P504S) in Atypical Adenomatous Hyperplasia of the Prostate , 2002, The American journal of surgical pathology.

[57]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[58]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[59]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[60]  J. Trent,et al.  Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. , 2002, Cancer research.

[61]  S. Reed,et al.  P504S: A New Molecular Marker for the Detection of Prostate Carcinoma , 2001, The American journal of surgical pathology.

[62]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[63]  G. Miller,et al.  Molecular analysis of multifocal prostate cancer lesions , 1999, The Journal of pathology.